A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults with Asthma

Trial Identifier: D8210C00005
Sponsor: AstraZeneca
Start Date: July 2024
Primary Completion Date: August 2026
Study Completion Date: August 2026
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Calgary, AB, CA, T2N 4Z6
CA, BC North Vancouver, BC, CA, V7L 2L7
CA, QC Montreal, QC, CA, H4A 3J1
CA, QC Quebec, QC, CA, G1V 4G5
DE Essen, DE, 45239
DE Frankfurt, DE, 60596
DE Frankfurt/Main, DE, 60389
DE Grosshansdorf, DE, 22927
DE Peine, DE, 31224
DK Aalborg, DK, 9100
DK Hvidovre, DK, 2650
DK Vejle, DK, 7100
ES Barcelona, ES, 08035
ES Santander, ES, 39008
GB Birmingham, GB, B9 5SS
GB Leicester, GB, LE3 9QP
GB Liverpool, GB, L7 8YE
GB London, GB, W12 0HS
GB Manchester, GB, M23 9QZ
GB Oxford, GB, OX3 7LE
GB Southampton, GB, SO9 4XY